ICU Medical, Inc. (ICUI)

ICU Medical beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 6, even as profits fell year over year. Revenue rose 0.5% to roughly $551.7 million (up from about $548.9 million a year ago) and topped the $533.4 million estimate (+3.4%), with Infusion Consumables, its largest segment, growing ~6% to about $289.3 million and Infusion Systems rising ~13% to around $189.0 million, while Vital Care declined ~32% to roughly $73.4 million. Adjusted EPS of $2.37 topped the $1.91 estimate (+24.1%). On profitability, gross profit was about $235.1 million with gross margin near 43%, and operating income came in around $39.1 million with operating margin roughly 7%. Net income fell 46% year over year to about $19.1 million (down from roughly $35.3 million a year ago), and the company generated operating cash flow of about $80.2 million. For the next period, consensus calls for EPS of $2.13 on revenue of $552.1 million.